Bristol-Myers Squibb (NYSE:BMY) Shares Bought by Brevan Howard Capital Management LP

Brevan Howard Capital Management LP grew its holdings in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 289.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 142,886 shares of the biopharmaceutical company's stock after acquiring an additional 106,230 shares during the period. Brevan Howard Capital Management LP's holdings in Bristol-Myers Squibb were worth $8,082,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Norges Bank acquired a new position in Bristol-Myers Squibb in the fourth quarter valued at approximately $1,989,525,000. Ameriprise Financial Inc. increased its holdings in shares of Bristol-Myers Squibb by 59.9% during the 4th quarter. Ameriprise Financial Inc. now owns 32,079,246 shares of the biopharmaceutical company's stock valued at $1,814,341,000 after purchasing an additional 12,011,983 shares in the last quarter. Wellington Management Group LLP lifted its stake in shares of Bristol-Myers Squibb by 3,880.0% in the 4th quarter. Wellington Management Group LLP now owns 5,977,505 shares of the biopharmaceutical company's stock valued at $338,088,000 after purchasing an additional 5,827,317 shares during the period. Raymond James Financial Inc. acquired a new stake in Bristol-Myers Squibb during the fourth quarter valued at $257,618,000. Finally, Schroder Investment Management Group increased its holdings in Bristol-Myers Squibb by 49.7% in the fourth quarter. Schroder Investment Management Group now owns 11,413,428 shares of the biopharmaceutical company's stock valued at $639,837,000 after buying an additional 3,787,075 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company's stock.

Insiders Place Their Bets

In other Bristol-Myers Squibb news, EVP Samit Hirawat bought 4,250 shares of the firm's stock in a transaction dated Friday, April 25th. The stock was acquired at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the completion of the purchase, the executive vice president now owns 83,513 shares of the company's stock, valued at approximately $3,973,548.54. This represents a 5.36 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.09% of the stock is currently owned by insiders.

Bristol-Myers Squibb Stock Performance

Shares of BMY traded down $0.85 during midday trading on Thursday, reaching $46.77. 23,400,579 shares of the stock were exchanged, compared to its average volume of 13,071,191. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $63.33. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15. The company has a market capitalization of $95.18 billion, a price-to-earnings ratio of -10.58, a PEG ratio of 2.07 and a beta of 0.39. The business's 50-day moving average price is $55.06 and its 200 day moving average price is $56.27.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping the consensus estimate of $1.50 by $0.30. The company had revenue of $11.20 billion for the quarter, compared to analyst estimates of $10.77 billion. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The firm's revenue was down 5.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($4.40) earnings per share. On average, sell-side analysts expect that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, May 1st. Investors of record on Friday, April 4th were paid a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a yield of 5.30%. The ex-dividend date was Friday, April 4th. Bristol-Myers Squibb's dividend payout ratio is currently 92.88%.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on BMY. The Goldman Sachs Group restated a "neutral" rating and set a $55.00 target price (down from $67.00) on shares of Bristol-Myers Squibb in a research report on Tuesday, April 8th. Cantor Fitzgerald reissued a "neutral" rating and issued a $55.00 price objective on shares of Bristol-Myers Squibb in a report on Tuesday, April 22nd. Piper Sandler began coverage on Bristol-Myers Squibb in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 target price for the company. Wells Fargo & Company lifted their price target on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an "equal weight" rating in a research note on Friday, February 7th. Finally, Argus upgraded shares of Bristol-Myers Squibb to a "hold" rating in a research report on Friday, April 25th. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have assigned a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $58.00.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.